CAR-TCR Europe 2020

Call for Papers

With CAR-T therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for.

The CAR-TCR Summit Europe will unravel the technical challenges across translation, scale and delivery to provide your team with the platform to learn, collaborate and gain actionable insights to advance your therapy for clinical and commercial success.

This year's focused agenda will delve into the technical bottlenecks encountered in every stage of the CAR-TCR drug development cycle, providing more comprehensive analysis across 3 tracks including:

Translation Track

- Define parameters to select and expand optimal T cell products with Gracell and TCBiopharm

- Overcome tumour resistance to improve the durability of response with CARsgen Therapeutics

- Strategies to manage toxicity with Kite and Eureka Therapeutics - Improve tumour targeting and safety profiles of allogeneic therapies with GammaDelta Therapeutics

Manufacturing Track

- Technology to disrupt current processes to shorten manufacturing times with Immatics and Gadeta

- CMC control to develop consistent quality products with Alliance of Regenerative Medicine

- Overcome vector supply bottlenecks with GlaxoSmithKline

- Carry out technology transfer with guidance from EMA

Development and Commercialisation Track

- Lessons learned in clinical development decision making from GlaxoSmithKline and Marker Therapeutics

-Gain regulatory guidance to initiate clinical trials in Europe from MHRA and Celgene -Address early evidence criteria to achieve access and reimbursement with NICE and bluebird bio

-Review the operational challenges of running an effective CAR-T allogeneic trial with the NHS

Building an industry-focused agenda with insights from experts at Celgene, Refuge Biotech, Celyad, ICER, Immatics, Medigene, Allogene Therapeutics, Leucid Bio, T-Knife, GSK and many more, this agenda is tailored to your, and the industry's, needs.

URL:

Brochure: https://go.evvnt.com/543432-3?pid=6586

Prices:

Pharma and Biotech Drug Developer - Conference + Workshop + Focus Day: GBP 3197.0,

Pharma and Biotech Drug Developer - Conference + Focus Day: GBP 2598.0,

Pharma and Biotech Drug Developer - Conference + Workshop Day: GBP 2598.0,

Pharma and Biotech Drug Developer - Conference Only: GBP 1799.0,

Academic - Conference + Workshop + Focus Day: GBP 2217.0,

Academic - Conference + Focus Day: GBP 1798.0,

Academic - Conference + Workshop Day: GBP 1798.0,

Academic - Conference Only: GBP 1299.0,

Academic - Workshop Day Only: GBP 599.0,

Academic - Focus Day Only: GBP 599.0

Speakers: Adrian Bott, Kite, a Gilead Company, Alessandra Cesano, ESSA, Ali Mohamad, Immatics, Alice Brown, GammaDelta Therapeutics, Amol Ketcar, GlaxoSmithKline, Annie Hubert, Alliance for Regenerative Medicine, Blake Aftab, Atara Biotherapeutics, Cedrik Britten, GlaxoSmithKline, Cheng Liu, Eureka, David Gilham, Celyad, Deborah Morrison, National Institute for Health and Clinical Excellence, Delfi Krishna, GlaxoSmithKline, Dolores Schendel, Medigene, Francesco Marincola, Refuge Biotechnologies, Helen Tayton-Martin, Adaptimmune, Hong Ma, CARsgen Therapeutics, Jacquelyn Awigena-Cook, Celgene, Jens-Peter Marschner, Zelluna Immunotherapy, John Johnston, MHRA, John Maher, Leucid Bio, Kai Pinkernell, Medigene, Klaus Tressl, Medigene, Lothar Germeroth, Juno Therapeutics, Michael Koslowski, GammaDelta Therapeutics, Michael Leek, TCBiopharm, Michael Lehmicke, Alliance for Regenerative Medicine, Mythili Koneru, Marker Therapeutics, Namir Hassan, Zelluna Therapy, Peggy Sotiropoulou, Celyad, Andrew Sewell, Cardiff University, Qasim Rafiq, University College London, Reuben Benjamin, Kings College Hospital NHS, Stefanos Theoharis, Cell Medica, Therese Solstad Saunders, Norwegian Medicines Agency, Tol Trimborn, Gadeta, William Cao, Gracell, Yannick Bulliard, Immatics, Aura Mackenzie, bluebird bio, Agnes Schubert, Novartis, Peter Olagunju, bluebird bio, Valeria Judkowski, Kite, a Gilead Company, Therese Choquette, Novartis

Time: 9:00 am to 5:00 pm